MedPath

The effect of atorvastatin plus aspirin compared with a non-therapeutic substance on the function of the blood vessels and inflammation in HIV patients under treatment presenting a low risk of cardiovascular disease.

Not Applicable
Recruiting
Conditions
Human immunodeficiency virus [HIV] disease resulting in other conditions
Registration Number
RBR-39bjm4
Lead Sponsor
Hospital das Clínicas da Universidade Federal de Pernambuco
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria

HIV patients on antiretroviral use ; both genders , aged between 18 and 60; lower cardiovascular risk than 10 % probability of occurrence of cardiovascular events in 10 years , as measured by the Framingham risk score .

Exclusion Criteria

history of hospitalization and opportunistic infections in the past 90 days; history of chronic liver dysfunction, thyroid dysfunction, autoimmune disease, history of hepatitis B or C; pregnancy or breastfeeding; previous use of statins, fibrates, ezetemibe, omega 3 , aspirin, NSAIDs, oral anticoagulants, interferon, interleukins, growth hormones, immunoglobulins, glucocorticoids or other immunosuppressants; alcohol abuse; previous intolerance to statins and aspirin; hemophilia; AST and ALT greater or equal 120 IU / L; CPK grater ou equal 167 U / L; muscle trauma or recent surgery performed until four months earlier; history of cardiovascular disease, diabetes, cancer and renal dysfunction.

Study & Design

Study Type
Intervention
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Difference by 10% or more in diameter of the brachial artery at rest and after stimulation with redness , measured at time zero , after 3 months and 6 months in Doppler ultrasound device .
Secondary Outcome Measures
NameTimeMethod
• Reduced levels of inflammatory mediators by 25% (IFN-gama, IL-1, IL-6, IL-10, MCP-1, NT-PROBNP, TNF-alfa, VEGF e PCR) in peripheral blood in week 0, 12 and 24 <br>• Occurrence of adverse events, including epigastric pain and / or muscle pain, fatigue, transaminase elevation and Creatine phosphokinase in monthly medical visits.<br>• 25% reduction in the levels of triglycerides , total cholesterol and fractions at weeks 0 , 12 and 24 observed in biochemical tests of peripheral blood.
© Copyright 2025. All Rights Reserved by MedPath